TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06152029

Intervention type: DEVICE
Intervention: Temporary PNS system
Description: This system remains in place up to 60 days, then removed.
Study: NCT06103734

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Zavegepant 10 mg
Description: 4 doses of zavegpant 10 mg intranasal spray device

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Control 1
Description: 3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Control 2
Description: 3 doses of placebo intranasal spray device and 1 dose of zavegepant 10 mg intranasal spray device
Study: NCT06479018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Venous blood sampling will be carried out for each patient included in the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Venous blood sampling will be carried out for each patient included in the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid bubble sampling
Description: Liquid bubble sampling will be carried out for each patients with Bullous Pemphigoid included in the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cutaneous biopsy
Description: At least the first cutaneous biopsy will be carried out for each patients with Bullous Pemphigoid included in the study.
Study: NCT05872321

Intervention type: OTHER
Intervention: Complication
Description: whether or not complications occur
Study: NCT05470374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative sonography
Description: ultrasound scanning of brain to search tumor remnants
Study: NCT06343363

Intervention type: BEHAVIORAL
Intervention: Early discharge protocol
Description: Patients admitted for transcatheter edge-to-edge repair to either mitral or tricuspid valve and then discharged within 36 hours
Study: NCT05673993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept 80 mg
Description: Telitacicept 80 mg subcutaneously once a week.
Study: NCT05128305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine1 and traditional Chinese medicine 2
Description: We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine1 and traditional Chinese medicine 2
Description: We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine1 and traditional Chinese medicine 2
Description: We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: traditional Chinese medicine1 and traditional Chinese medicine 2
Description: We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
Study: NCT05527483

Intervention type: DRUG
Intervention: [68Ga]PSMA
Description: Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging

Intervention type: DRUG
Intervention: [68Ga]PSMA
Description: Patients will receive up to 6 mCi of \[Ga-68\]PSMA delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging

Intervention type: DRUG
Intervention: Flourine-18 [F-18] Sodium Fluoride (NaF)
Description: Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.

Intervention type: DRUG
Intervention: Flourine-18 [F-18] Sodium Fluoride (NaF)
Description: Patients will receive 8-12 mCi of \[F-18\]NaF delivered as an intravenous (IV) bolus injection, followed by digital PET/CT imaging.
Study: NCT06322940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 250 mL serving size, 3.25% fat content
Description: Milk
Study: NCT05673993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept 160 mg
Description: Telitacicept 160 mg subcutaneously once a week.
Study: NCT06322940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 175 g serving size, ≥2% fat content
Description: Yogurt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50 g serving size, ≥28% fat content
Description: Cheese
Study: NCT06043154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients with severe to extreme anorexia nervosa admitted to hospital for refeeding
Description: Clinical and biological measurements, blood and stool sample collection
Study: NCT05548283

Intervention type: DRUG
Group type: OTHER
Intervention: Beta-lactam antibiotic
Description: Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).

Intervention type: DRUG
Group type: OTHER
Intervention: Beta-lactam antibiotic
Description: Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).

Intervention type: DRUG
Group type: OTHER
Intervention: Aminoglycoside
Description: Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
Study: NCT05673993

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given subcutaneous placebo once a week.
Study: NCT05527483

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT
Description: Patients will receive \[68Ga\]PSMA with a PET/CT and Flourine-18 \[F-18\] Sodium Fluoride (NaF) with a PET/CT

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT
Description: Patients will receive \[68Ga\]PSMA with a PET/CT and Flourine-18 \[F-18\] Sodium Fluoride (NaF) with a PET/CT
Study: NCT06513949

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atibuclimab
Description: monoclonal antibody against human CD14
Study: NCT05951101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith LAA Occlusion System
Description: LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 17 mm and 25 mm
Study: NCT05518045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously
Study: NCT06513949

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline for injection
Study: NCT05050227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cCBT Enhanced Collaborative Care
Description: Computerized CBT (cCBT) will be delivered supported by a depression care manger who will facilitate access to cCBT, promote and monitor cCBT use, reinforce CBT concepts (during outside CBT session homework), and monitor mental health symptoms for each participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Primary Care Provider supported usual care typically includes medication prescription and referrals to specialty mental health, including Primary Care - Mental Health Integration services.
Study: NCT06479278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talk with Me Baby
Description: Primary care providers will embed Talk With Me Baby (TWMB) within standard-of-care Well-Child Care visits for children ≤36 months of age. Children will receive usual care plus a brief language-promotion intervention (TWMB) in up to 4 consecutive Well-Child Care visits during their 12-month period.
Study: NCT05518045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Administered intravenously
Study: NCT05923255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）
Description: Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRH（Traditional Laparoscopic Right Hemicolectomy）
Description: Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.
Study: NCT05223192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy Entrainment with Ocean Disc Intervention
Description: The studied intervention regards live entrainment with the ocean disc. Entrainment involves the use of an external stimulus, in the case of this study, an ocean disc instrument. Motion of the disc creates sounds in synchrony with the breathing of the infant and then in turn can control and influence the infant's regulation of the breath.
Study: NCT05481502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: 3 biopsies will be collected: at baseline, at day+15 and optionally at relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow sample
Description: If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
Study: NCT04756050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine HCl % 2 injectable solution
Description: 20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5mcg adrenaline per ml.(9ml bupivacaine, 9ml prilocaine and 2ml saline with 50 mcg adrenaline per ml)
Study: NCT06090552

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Letter, AD, PREPARE
Description: Letter, AD, PREPARE

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Letter, AD, PREPARE, reminders
Description: Letter, AD, PREPARE, reminders
Study: NCT05264337

Intervention type: OTHER
Intervention: Self-reported lymphedema
Description: Lymphedema as reported by LymQOL questionnaire.

Intervention type: OTHER
Intervention: Self-reported lymphedema
Description: Lymphedema as reported by LymQOL questionnaire.

Intervention type: OTHER
Intervention: Self-reported lymphedema
Description: Lymphedema as reported by LymQOL questionnaire.
Study: NCT05231369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChulaCov19 BNA159 mRNA vaccine
Description: ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChulaCov19 BNA159 mRNA vaccine
Description: ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine
Study: NCT05264337

Intervention type: OTHER
Intervention: Self-reported lymphedema
Description: Lymphedema as reported by LymQOL questionnaire.
Study: NCT04912375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming intervention
Description: The pilot RCT will ask participants to complete a simple word-searching exercise as a goal-priming of healthy eating and can be completed in 5 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming intervention
Description: The pilot RCT will ask participants to complete a simple word-searching exercise as a goal-priming of healthy eating and can be completed in 5 min.
Study: NCT04980495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod concentrate for solution for infusion 20 mg/mL
Description: Patients receiving efgartigimod IV treatment in a continuous treatment regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod concentrate for solution for infusion 20 mg/mL
Description: Patients receiving efgartigimod IV treatment in a cyclic treatment regimen
Study: NCT05264337

Intervention type: OTHER
Intervention: Dielectric constant ratio
Description: Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.

Intervention type: OTHER
Intervention: Limb volume
Description: Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
Study: NCT06269874

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: microvascular function assessment
Description: mircovascular function parameters will be measured by administering adenosine in two different pathways

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: microvascular function assessment
Description: mircovascular function parameters will be measured by administering adenosine in two different pathways
Study: NCT06615310

Intervention type: OTHER
Intervention: ultrasonograpic evaluotion
Description: The distance between the hyoid and thyroid cartilage, the volume of the geniohyoid, digastric anterior, sternohyoid and thyrohyoid muscles will be evaluated by ultrasound.

Intervention type: OTHER
Intervention: ultrasonograpic evaluotion
Description: The distance between the hyoid and thyroid cartilage, the volume of the geniohyoid, digastric anterior, sternohyoid and thyrohyoid muscles will be evaluated by ultrasound.
Study: NCT06611163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Description: Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injection at Day 1 and Week 4
Study: NCT06610344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R-1,3-Butanediol
Description: R-1,3-Butanediol 35 mL
Study: NCT06618898

Intervention type: OTHER
Intervention: online questionnaire
Description: The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.

Intervention type: OTHER
Intervention: online questionnaire
Description: The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.

Intervention type: OTHER
Intervention: online questionnaire
Description: The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.

Intervention type: OTHER
Intervention: online questionnaire
Description: The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.

Intervention type: OTHER
Intervention: online questionnaire
Description: The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.
Study: NCT06620302

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bcl-XL Proteolysis Targeting Chimera DT2216
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (drug)
Description: Given IV
Study: NCT05602779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tVns Program
Description: Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone App Program
Description: Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.
Study: NCT06323187

Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical Sampling
Description: Each participant will provide a sample of fluid or mucus collected from the uterine endocervix.
Study: NCT06629545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: irrigation activation with PUI
Description: The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device. The power setting of the ultrasonic device was 30% (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 2.5% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 1 mm behind the working length without touching the canal walls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: irrigation with sonic activation
Description: A suitable-size activator tip (#25/.04) attached to an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA) was inserted into the canal 1 mm short of the working length. 3 ml of 2.5% NaOCl solution was activated in three periods of 20 s (1 ml of 2.5% NaOCl in each cycle). Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
Study: NCT06631404

Intervention type: DIAGNOSTIC_TEST
Intervention: renal doppler
Description: doppler srudy on renal arteries bilaterally , and detection of RI of renal artery

Intervention type: DIAGNOSTIC_TEST
Intervention: renal doppler
Description: doppler srudy on renal arteries bilaterally , and detection of RI of renal artery
Study: NCT06629116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients with AIS receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).
Description: Whether to administer albumin to AIS patients after intravascular thrombectomy and reperfusion.
Study: NCT06628427

Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA Test
Description: MoCA (Montreal Cognitive Assessment or The MoCA Test) was validated as a highly sensitive tool for early detection of mild cognitive impairment (MCI) in hundreds of peer-reviewed studies since 2000. MoCA has been widely adopted in clinical settings and used in academic and non-academic research around the world. The sensitivity of MoCA for detecting MCI is 90%, compared to 18% for the MMSE. Prospective participants meeting the eligibility criteria, as determined by the Montreal Cognitive Assessment (MoCA) test, will be invited to the Brain- Computer Interface (BCI) laboratory at the Kroto Research Centre on the University of Sheffield north campus to participate in the study.

Intervention type: DEVICE
Intervention: Random Dot Motion (RDM) task
Description: Random Dot Motion task (RDM) has been widely used in research on spatial attention, and decision-making ability, etc., and its results (accuracy and reaction time) can be used as indicators to detect spatial attention. During the assessment, participants were required to monitor a series of dots in constant random motion on the screen. The dots sometimes moved coherently together to the left or right, and participants were required to press the left mouse button when they perceived them moving to the left and the right mouse button when they observed them moving to the right. We are going to use the motion coherence level of 50%. The higher the coherence level, the greater the number of dots moving together, and the combination of the moving direction and coherence level of the dots appear randomly during the task.

Intervention type: DEVICE
Intervention: P300-BCI task without feedback
Description: Two different speller matrix sizes: 3×3 and 5×5, two inter-stimulus intervals (ISIs): 117ms (i.e., commonly used ISI for healthy adults) and 175ms (i.e., 50% longer than the widely used ISI) and two spelling words (QUICK and JUMP) are designed in this experiment to explore the calibration accuracy of these eight parameter combinations in the young and old groups and obtain the best parameter combination. The matrix contains letters and digits, and the target letters will be displayed below the matrix letter by letter. When the speller runs, the rows and columns in the matrix will flash 15 times each randomly. Each flash will last for 55ms, and the subsequent ISI will last for different times according to different parameter designs. Participants only need to focus on the target letter and silently count the number it flashes, as flashing target letters can generate P300 if well attended.